Long-term complete remission in IgD-myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Case Studies

Background:

• IgD multiple myeloma (MM) is a rare subtype of plasma cell disorder.
• Complete and long-term remission in IgD-MM is exceptionally uncommon.
• Conventional chemotherapy regimens are often less effective in IgD-MM compared to other myeloma types.

Observation:

• A patient diagnosed with stage IIIB IgD-MM was treated with standard melphalan and prednisone chemotherapy.
• The patient achieved complete disappearance of monoclonal protein after four cycles of treatment.
• Therapy was completed after 14 cycles, with a subsequent follow-up period exceeding 8 years.

Findings:

• The patient has maintained a complete remission for over 8 years post-treatment.
• This sustained remission suggests a potential cure for IgD-MM, even with adverse prognostic factors.
• The case demonstrates the efficacy of conventional chemotherapy in achieving long-term outcomes for a rare myeloma variant.

Implications:

• This case provides a rare example of a potential cure for IgD multiple myeloma.
• It suggests that conventional chemotherapy may be effective in select IgD-MM patients.
• Further research into IgD-MM treatment strategies is warranted, given its rarity and poor prognosis.